<?xml version="1.0" encoding="ISO-8859-1"?><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
<front>
<journal-meta>
<journal-id>2340-9894</journal-id>
<journal-title><![CDATA[Ars Pharmaceutica (Internet)]]></journal-title>
<abbrev-journal-title><![CDATA[Ars Pharm]]></abbrev-journal-title>
<issn>2340-9894</issn>
<publisher>
<publisher-name><![CDATA[Universidad de Granada]]></publisher-name>
</publisher>
</journal-meta>
<article-meta>
<article-id>S2340-98942025000200233</article-id>
<article-id pub-id-type="doi">10.30827/ars.v66i2.31635</article-id>
<title-group>
<article-title xml:lang="en"><![CDATA[Gradual dose reduction versus abrupt deprescription of antipsychotic in patients with dementia: A systematic review]]></article-title>
<article-title xml:lang="es"><![CDATA[Reducción gradual de dosis frente a deprescripción abrupta de antipsicóticos en pacientes con demencia: una revisión sistemàtica]]></article-title>
</title-group>
<contrib-group>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Oyarzo Cuevas]]></surname>
<given-names><![CDATA[Alex]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
<xref ref-type="aff" rid="Aaf"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Martín Ruiz]]></surname>
<given-names><![CDATA[Eva]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
<xref ref-type="aff" rid="Aaf"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Olry de Labry Lima]]></surname>
<given-names><![CDATA[Antonio]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
<xref ref-type="aff" rid="Aaf"/>
<xref ref-type="aff" rid="A a"/>
<xref ref-type="aff" rid="A7"/>
</contrib>
</contrib-group>
<aff id="Af1">
<institution><![CDATA[,University of Seville Public Health and Epidemiology ]]></institution>
<addr-line><![CDATA[ ]]></addr-line>
<country>Spain</country>
</aff>
<aff id="Af2">
<institution><![CDATA[,Austral University School of Speech Therapy and School of Psychology ]]></institution>
<addr-line><![CDATA[ ]]></addr-line>
<country>Chile</country>
</aff>
<aff id="Af3">
<institution><![CDATA[,Andalusian School of Public Health  ]]></institution>
<addr-line><![CDATA[Granada ]]></addr-line>
<country>Spain</country>
</aff>
<aff id="Af4">
<institution><![CDATA[,Universidad de Sevilla Nursing department ]]></institution>
<addr-line><![CDATA[ ]]></addr-line>
<country>Spain</country>
</aff>
<aff id="Af5">
<institution><![CDATA[,Andalusian School of Public Health Andalusian Center for Documentation and Information on Medicines (CADIME) ]]></institution>
<addr-line><![CDATA[Granada ]]></addr-line>
<country>Spain</country>
</aff>
<aff id="Af6">
<institution><![CDATA[,CIBER en Epidemiología y Salud Pública (CIBERESP)  ]]></institution>
<addr-line><![CDATA[Madrid ]]></addr-line>
<country>Spain</country>
</aff>
<aff id="Af7">
<institution><![CDATA[,Universidad de Granada Instituto de Investigación Biosanitaria ]]></institution>
<addr-line><![CDATA[Granada ]]></addr-line>
<country>Spain</country>
</aff>
<pub-date pub-type="pub">
<day>00</day>
<month>06</month>
<year>2025</year>
</pub-date>
<pub-date pub-type="epub">
<day>00</day>
<month>06</month>
<year>2025</year>
</pub-date>
<volume>66</volume>
<numero>2</numero>
<fpage>233</fpage>
<lpage>246</lpage>
<copyright-statement/>
<copyright-year/>
<self-uri xlink:href="http://scielo.isciii.es/scielo.php?script=sci_arttext&amp;pid=S2340-98942025000200233&amp;lng=en&amp;nrm=iso"></self-uri><self-uri xlink:href="http://scielo.isciii.es/scielo.php?script=sci_abstract&amp;pid=S2340-98942025000200233&amp;lng=en&amp;nrm=iso"></self-uri><self-uri xlink:href="http://scielo.isciii.es/scielo.php?script=sci_pdf&amp;pid=S2340-98942025000200233&amp;lng=en&amp;nrm=iso"></self-uri><abstract abstract-type="short" xml:lang="en"><p><![CDATA[Abstract  Objective:  To synthesize the available evidence on antipsychotic gradual dose reduction or abrupt deprescription in the older people population with dementia.  Methods:  A systematic review of intervention studies. PubMed, Embase, Web of Science-Core Collection, Cochrane Library, Scopus, MEDLINE(Ovid), and PsycINFO databases were consulted. Articles were eligible for inclusion if they were intervention studies (randomized or quasi-experimental trials) evaluating the effectiveness of dose reduction or complete withdrawal antipsychotic deprescribing strategies in people with dementia. The screening process, data extraction, data analysis and bias risk assessment were performed by two independent reviewers and any discrepancies were triangulated with a third reviewer.  Results:  Eight clinical trials were ultimately included in the systematic review, two of which were quasi experimental. Over 60% of participants came from nursing or care homes. There is evidence of several strategies for deprescribing antipsychotics. Five studies used an abrupt withdrawal schedule and three studies used a gradual dose reduction. Deprescription through abrupt and gradual withdrawal schedules showed no significant differences in the management of behavioral symptoms, although abrupt withdrawals showed significantly higher rates of relapse and/or adverse events.  Conclusion:  Deprescribing antipsychotics is feasible in those people with dementia, and it is associated with benefits in terms of survival, and with potential improved outcomes in the management and relapse of behavioral and psychological symptoms of dementia. It seems reasonable that tapering off antipsychotic medication should be assessed after 12 weeks of treatment or when behavioural symptoms are under control.]]></p></abstract>
<abstract abstract-type="short" xml:lang="es"><p><![CDATA[Resumen  Objetivo:  Sintetizar la evidencia disponible sobre la reducción gradual de la dosis de antipsicóticos o su deprescripción abrupta en personas mayores con demencia.  Métodos:  Revisión sistemática de estudios de intervención. Se consultaron las bases de datos PubMed, Embase, Web of Science-Core Collection, Cochrane Library, Scopus, MEDLINE (Ovid) y PsycINFO. Se incluyeron estudios (ensayos aleatorios o cuasiexperimentales) que evaluaban la efectividad de estrategias de deprescripción de antipsicóticos de reducción de dosis o abstinencia completa. Dos revisores independientes, triangulando por un tercer revisor realizaron el proceso de selección, extracción y análisis de datos, y evaluación del riesgo de sesgo.  Resultados:  Se incluyeron 8 ensayos clínicos en la revisión sistemática, dos de los cuales fueron cuasi experimentales. Más del 60% de los participantes procedían de residencias de personas ancianas. Existe evidencia de varias estrategias para deprescribir antipsicóticos. Cinco estudios utilizaron un calendario de retiro abrupto y tres estudios utilizaron una reducción gradual de la dosis. La deprescripción mediante esquemas de retiro abrupto y gradual no mostró diferencias significativas en el manejo de los síntomas conductuales, y mostraron tasas significativamente más altas de recaída y/o eventos adversos.  Conclusión:  La deprescripción de antipsicóticos es factible en personas con demencia, y se asocia a beneficios en términos de supervivencia y con posibles mejoras en el manejo y la recaída de los síntomas conductuales y psicológicos de la demencia. Parece razonable que la reducción gradual de la medicación antipsicótica se evalúe después de 12 semanas de tratamiento o cuando los síntomas conductuales estén bajo control.]]></p></abstract>
<kwd-group>
<kwd lng="es"><![CDATA[Demencia]]></kwd>
<kwd lng="es"><![CDATA[Antipsicóticos]]></kwd>
<kwd lng="es"><![CDATA[Prescripción inadecuada]]></kwd>
<kwd lng="es"><![CDATA[Deprescribir]]></kwd>
<kwd lng="es"><![CDATA[Síntomas conductuales]]></kwd>
<kwd lng="en"><![CDATA[Dementia]]></kwd>
<kwd lng="en"><![CDATA[Antipsychotic Agents]]></kwd>
<kwd lng="en"><![CDATA[Inappropriate prescribing]]></kwd>
<kwd lng="en"><![CDATA[Behavioral Symptoms]]></kwd>
</kwd-group>
</article-meta>
</front><back>
<ref-list>
<ref id="B1">
<label>1</label><nlm-citation citation-type="journal">
<collab>The Lancet Public Health</collab>
<article-title xml:lang=""><![CDATA[Will dementia hamper healthy ageing?]]></article-title>
<source><![CDATA[Lancet Public Health]]></source>
<year>2022</year>
<volume>7</volume>
<numero>2</numero>
<issue>2</issue>
</nlm-citation>
</ref>
<ref id="B2">
<label>2</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Nichols]]></surname>
<given-names><![CDATA[E]]></given-names>
</name>
<name>
<surname><![CDATA[Steinmetz]]></surname>
<given-names><![CDATA[J D]]></given-names>
</name>
<name>
<surname><![CDATA[Vollset]]></surname>
<given-names><![CDATA[S E]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Estimation of the global prevalence of dementia in 2019 and forecasted prevalence in 2050: an analysis for the Global Burden of Disease Study 2019]]></article-title>
<source><![CDATA[Lancet Public Health]]></source>
<year>2022</year>
<volume>7</volume>
<numero>2</numero>
<issue>2</issue>
<page-range>e105-25</page-range></nlm-citation>
</ref>
<ref id="B3">
<label>3</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Cahill]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[WHO&#8217;s global action plan on the public health response to dementia: some challenges and opportunities]]></article-title>
<source><![CDATA[Aging Ment Health]]></source>
<year>2020</year>
<volume>24</volume>
<numero>2</numero>
<issue>2</issue>
<page-range>197-9</page-range></nlm-citation>
</ref>
<ref id="B4">
<label>4</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Wimo]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Jönsson]]></surname>
<given-names><![CDATA[L]]></given-names>
</name>
<name>
<surname><![CDATA[Bond]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Prince]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Winblad]]></surname>
<given-names><![CDATA[B]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[The worldwide economic impact of dementia 2010]]></article-title>
<source><![CDATA[Alzheimers Dement]]></source>
<year>2013</year>
<volume>9</volume>
<numero>1</numero>
<issue>1</issue>
<page-range>1-11.e3</page-range></nlm-citation>
</ref>
<ref id="B5">
<label>5</label><nlm-citation citation-type="">
<collab>World Health Organization</collab>
<source><![CDATA[Dementia]]></source>
<year>2023</year>
</nlm-citation>
</ref>
<ref id="B6">
<label>6</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Prince]]></surname>
<given-names><![CDATA[M J]]></given-names>
</name>
<name>
<surname><![CDATA[de Rodríguez]]></surname>
<given-names><![CDATA[J L]]></given-names>
</name>
<name>
<surname><![CDATA[Noriega]]></surname>
<given-names><![CDATA[L]]></given-names>
</name>
<name>
<surname><![CDATA[López]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Acosta]]></surname>
<given-names><![CDATA[D]]></given-names>
</name>
<name>
<surname><![CDATA[Albanese]]></surname>
<given-names><![CDATA[E]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[The 10/66 Dementia Research Group&#8217;s fully operationalised DSM-IV dementia computerized diagnostic algorithm, compared with the 10/66 dementia algorithm and a clinician diagnosis: a population validation study]]></article-title>
<source><![CDATA[BMC Public Health]]></source>
<year>2008</year>
<volume>8</volume>
</nlm-citation>
</ref>
<ref id="B7">
<label>7</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Ma]]></surname>
<given-names><![CDATA[H]]></given-names>
</name>
<name>
<surname><![CDATA[Lu]]></surname>
<given-names><![CDATA[X]]></given-names>
</name>
<name>
<surname><![CDATA[Zhou]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Clinical Practice Guidelines for the Management of Behavioral and Psychological Symptoms of Dementia: A Systematic Review with AGREE II]]></article-title>
<source><![CDATA[Front Neurol]]></source>
<year>2022</year>
<volume>13</volume>
</nlm-citation>
</ref>
<ref id="B8">
<label>8</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[García-Alberca]]></surname>
<given-names><![CDATA[J M]]></given-names>
</name>
<name>
<surname><![CDATA[Lara Muñoz]]></surname>
<given-names><![CDATA[J P]]></given-names>
</name>
<name>
<surname><![CDATA[Berthier Torres]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Sintomatología neuropsiquiátrica y conductual en la enfermedad de Alzheimer]]></article-title>
<source><![CDATA[Actas Esp Psiquiatr]]></source>
<year>2010</year>
<volume>38</volume>
<numero>4</numero>
<issue>4</issue>
<page-range>212-22</page-range></nlm-citation>
</ref>
<ref id="B9">
<label>9</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Kirkham]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Sherman]]></surname>
<given-names><![CDATA[C]]></given-names>
</name>
<name>
<surname><![CDATA[Velkers]]></surname>
<given-names><![CDATA[C]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Antipsychotic Use in Dementia]]></article-title>
<source><![CDATA[Can J Psychiatry]]></source>
<year>2017</year>
<volume>62</volume>
<numero>3</numero>
<issue>3</issue>
<page-range>170-81</page-range></nlm-citation>
</ref>
<ref id="B10">
<label>10</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Tampi]]></surname>
<given-names><![CDATA[R R]]></given-names>
</name>
<name>
<surname><![CDATA[Tampi]]></surname>
<given-names><![CDATA[D J]]></given-names>
</name>
<name>
<surname><![CDATA[Balachandran]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Antipsychotics, Antidepressants, Anticonvulsants, Melatonin, and Benzodiazepines for Behavioral and Psychological Symptoms of Dementia: a Systematic Review of Meta-analyses]]></article-title>
<source><![CDATA[Curr Treat Options Psych]]></source>
<year>2017</year>
<volume>4</volume>
<numero>1</numero>
<issue>1</issue>
<page-range>55-79</page-range></nlm-citation>
</ref>
<ref id="B11">
<label>11</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Ballard]]></surname>
<given-names><![CDATA[C]]></given-names>
</name>
<name>
<surname><![CDATA[Lana]]></surname>
<given-names><![CDATA[M M]]></given-names>
</name>
<name>
<surname><![CDATA[Theodoulou]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[A randomised, blinded, placebo-controlled trial in dementia patients continuing or stopping neuroleptics (the DART-AD trial)]]></article-title>
<source><![CDATA[PLoS Med]]></source>
<year>2008</year>
<volume>5</volume>
<numero>4</numero>
<issue>4</issue>
</nlm-citation>
</ref>
<ref id="B12">
<label>12</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Rogowska]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Thornton]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Creese]]></surname>
<given-names><![CDATA[B]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Implications of Adverse Outcomes Associated with Antipsychotics in Older Patients with Dementia: A 2011-2022 Update]]></article-title>
<source><![CDATA[Drugs Aging]]></source>
<year>2023</year>
<volume>40</volume>
<numero>1</numero>
<issue>1</issue>
<page-range>21-32</page-range></nlm-citation>
</ref>
<ref id="B13">
<label>13</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Ballard]]></surname>
<given-names><![CDATA[C G]]></given-names>
</name>
<name>
<surname><![CDATA[Waite]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Birks]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Atypical antipsychotics for aggression and psychosis in Alzheimer&#8217;s disease]]></article-title>
<source><![CDATA[Cochrane Database Syst Rev]]></source>
<year>2006</year>
<numero>1</numero>
<issue>1</issue>
</nlm-citation>
</ref>
<ref id="B14">
<label>14</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Watt]]></surname>
<given-names><![CDATA[J A]]></given-names>
</name>
<name>
<surname><![CDATA[Thompson]]></surname>
<given-names><![CDATA[W]]></given-names>
</name>
<name>
<surname><![CDATA[Marple]]></surname>
<given-names><![CDATA[R]]></given-names>
</name>
<name>
<surname><![CDATA[Brown]]></surname>
<given-names><![CDATA[D]]></given-names>
</name>
<name>
<surname><![CDATA[Liu]]></surname>
<given-names><![CDATA[B]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Managing neuropsychiatric symptoms in patients with dementia]]></article-title>
<source><![CDATA[BMJ]]></source>
<year>2022</year>
<volume>376</volume>
</nlm-citation>
</ref>
<ref id="B15">
<label>15</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Schneider]]></surname>
<given-names><![CDATA[L S]]></given-names>
</name>
<name>
<surname><![CDATA[Dagerman]]></surname>
<given-names><![CDATA[K S]]></given-names>
</name>
<name>
<surname><![CDATA[Insel]]></surname>
<given-names><![CDATA[P]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Risk of Death with Atypical Antipsychotic Drug Treatment for Dementia]]></article-title>
<source><![CDATA[JAMA]]></source>
<year>2005</year>
<volume>294</volume>
<numero>15</numero>
<issue>15</issue>
<page-range>1934-43</page-range></nlm-citation>
</ref>
<ref id="B16">
<label>16</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Zuidema]]></surname>
<given-names><![CDATA[S U]]></given-names>
</name>
<name>
<surname><![CDATA[Johansson]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Selbaek]]></surname>
<given-names><![CDATA[G]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[A consensus guideline for antipsychotic drug use for dementia in care homes. Bridging the gap between scientific evidence and clinical practice]]></article-title>
<source><![CDATA[Int Psychogeriatr]]></source>
<year>2015</year>
<volume>27</volume>
<numero>11</numero>
<issue>11</issue>
<page-range>1849-59</page-range></nlm-citation>
</ref>
<ref id="B17">
<label>17</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Reeve]]></surname>
<given-names><![CDATA[E]]></given-names>
</name>
<name>
<surname><![CDATA[Gnjidic]]></surname>
<given-names><![CDATA[D]]></given-names>
</name>
<name>
<surname><![CDATA[Long]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Hilmer]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[A systematic review of the emerging definition of &#8220;deprescribing&#8221; with network analysis: Implications for future research and clinical practice]]></article-title>
<source><![CDATA[Br J Clin Pharmacol]]></source>
<year>2015</year>
<volume>80</volume>
<numero>6</numero>
<issue>6</issue>
<page-range>1254-68</page-range></nlm-citation>
</ref>
<ref id="B18">
<label>18</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Page]]></surname>
<given-names><![CDATA[M J]]></given-names>
</name>
<name>
<surname><![CDATA[McKenzie]]></surname>
<given-names><![CDATA[J E]]></given-names>
</name>
<name>
<surname><![CDATA[Bossuyt]]></surname>
<given-names><![CDATA[P M]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[The PRISMA 2020 statement: an updated guideline for reporting systematic reviews]]></article-title>
<source><![CDATA[BMJ]]></source>
<year>2021</year>
<volume>372</volume>
</nlm-citation>
</ref>
<ref id="B19">
<label>19</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Higgins]]></surname>
<given-names><![CDATA[J P T]]></given-names>
</name>
<name>
<surname><![CDATA[Altman]]></surname>
<given-names><![CDATA[D G]]></given-names>
</name>
<name>
<surname><![CDATA[Gøtzsche]]></surname>
<given-names><![CDATA[P C]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[The Cochrane Collaboration&#8217;s tool for assessing risk of bias in randomized trials]]></article-title>
<source><![CDATA[BMJ]]></source>
<year>2011</year>
<volume>343</volume>
</nlm-citation>
</ref>
<ref id="B20">
<label>20</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Page]]></surname>
<given-names><![CDATA[A T]]></given-names>
</name>
<name>
<surname><![CDATA[Clifford]]></surname>
<given-names><![CDATA[R M]]></given-names>
</name>
<name>
<surname><![CDATA[Potter]]></surname>
<given-names><![CDATA[K]]></given-names>
</name>
<name>
<surname><![CDATA[Schwartz]]></surname>
<given-names><![CDATA[D]]></given-names>
</name>
<name>
<surname><![CDATA[Etherton-Beer]]></surname>
<given-names><![CDATA[C D]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[The feasibility and effect of deprescribing in older adults on mortality and health: a systematic review and meta-analysis]]></article-title>
<source><![CDATA[Br J Clin Pharmacol]]></source>
<year>2016</year>
<volume>82</volume>
<numero>3</numero>
<issue>3</issue>
<page-range>583-623</page-range></nlm-citation>
</ref>
<ref id="B21">
<label>21</label><nlm-citation citation-type="">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Escudero]]></surname>
<given-names><![CDATA[T J]]></given-names>
</name>
<name>
<surname><![CDATA[Fernández]]></surname>
<given-names><![CDATA[V E]]></given-names>
</name>
<name>
<surname><![CDATA[Peris]]></surname>
<given-names><![CDATA[M J]]></given-names>
</name>
</person-group>
<source><![CDATA[Papel de los antipsicóticos en el tratamiento de los síntomas psicológicos y conductuales de los pacientes con demencia. Optimizando su prescripción]]></source>
<year>2021</year>
<publisher-loc><![CDATA[Valencia ]]></publisher-loc>
</nlm-citation>
</ref>
<ref id="B22">
<label>22</label><nlm-citation citation-type="journal">
<collab>CADIME</collab>
<article-title xml:lang=""><![CDATA[Polimedicación y deprescripción: recomendaciones prácticas]]></article-title>
<source><![CDATA[Bol Ter Andal]]></source>
<year>2021</year>
<volume>36</volume>
<numero>1</numero>
<issue>1</issue>
</nlm-citation>
</ref>
<ref id="B23">
<label>23</label><nlm-citation citation-type="journal">
<collab>CADIME</collab>
<article-title xml:lang=""><![CDATA[Antipsicóticos para el tratamiento de síntomas del comportamiento en las demencias]]></article-title>
<source><![CDATA[Bol Ter Andal]]></source>
<year>2018</year>
<volume>33</volume>
<numero>3</numero>
<issue>3</issue>
</nlm-citation>
</ref>
<ref id="B24">
<label>24</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[van Reekum]]></surname>
<given-names><![CDATA[R]]></given-names>
</name>
<name>
<surname><![CDATA[Clarke]]></surname>
<given-names><![CDATA[D]]></given-names>
</name>
<name>
<surname><![CDATA[Conn]]></surname>
<given-names><![CDATA[D]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[A randomized, placebo-controlled trial of the discontinuation of long-term antipsychotics in dementia]]></article-title>
<source><![CDATA[Int Psychogeriatr]]></source>
<year>2002</year>
<volume>14</volume>
<numero>2</numero>
<issue>2</issue>
<page-range>197-210</page-range></nlm-citation>
</ref>
<ref id="B25">
<label>25</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Ballard]]></surname>
<given-names><![CDATA[C]]></given-names>
</name>
<name>
<surname><![CDATA[Thomas]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Fossey]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[A 3-month, randomized, placebo-controlled, neuroleptic discontinuation study in 100 people with dementia: the neuropsychiatric inventory median cutoff is a predictor of clinical outcome]]></article-title>
<source><![CDATA[J Clin Psychiatry]]></source>
<year>2004</year>
<volume>65</volume>
<numero>1</numero>
<issue>1</issue>
<page-range>114-9</page-range></nlm-citation>
</ref>
<ref id="B26">
<label>26</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Ruths]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[Straand]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Nygaard]]></surname>
<given-names><![CDATA[H A]]></given-names>
</name>
<name>
<surname><![CDATA[Aarsland]]></surname>
<given-names><![CDATA[D]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Stopping antipsychotic drug therapy in demented nursing home patients: a randomized, placebo-controlled study. The Bergen District Nursing Home Study (BEDNURS)]]></article-title>
<source><![CDATA[Int J Geriatr Psychiatry]]></source>
<year>2008</year>
<volume>23</volume>
<numero>9</numero>
<issue>9</issue>
<page-range>889-95</page-range></nlm-citation>
</ref>
<ref id="B27">
<label>27</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Ballard]]></surname>
<given-names><![CDATA[C]]></given-names>
</name>
<name>
<surname><![CDATA[Hanney]]></surname>
<given-names><![CDATA[M L]]></given-names>
</name>
<name>
<surname><![CDATA[Theodoulou]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[The dementia antipsychotic withdrawal trial (DART-AD): long-term follow-up of a randomised placebo-controlled trial]]></article-title>
<source><![CDATA[Lancet Neurol]]></source>
<year>2009</year>
<volume>8</volume>
<numero>2</numero>
<issue>2</issue>
<page-range>151-7</page-range></nlm-citation>
</ref>
<ref id="B28">
<label>28</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Devanand]]></surname>
<given-names><![CDATA[D P]]></given-names>
</name>
<name>
<surname><![CDATA[Pelton]]></surname>
<given-names><![CDATA[G H]]></given-names>
</name>
<name>
<surname><![CDATA[Cunqueiro]]></surname>
<given-names><![CDATA[K]]></given-names>
</name>
<name>
<surname><![CDATA[Sackeim]]></surname>
<given-names><![CDATA[H A]]></given-names>
</name>
<name>
<surname><![CDATA[Marder]]></surname>
<given-names><![CDATA[K]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[A 6-month, randomized, double-blind, placebo-controlled pilot discontinuation trial after haloperidol response in Alzheimer&#8217;s disease]]></article-title>
<source><![CDATA[Int J Geriatr Psychiatry]]></source>
<year>2011</year>
<volume>26</volume>
<numero>9</numero>
<issue>9</issue>
<page-range>937-43</page-range></nlm-citation>
</ref>
<ref id="B29">
<label>29</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Devanand]]></surname>
<given-names><![CDATA[D P]]></given-names>
</name>
<name>
<surname><![CDATA[Pelton]]></surname>
<given-names><![CDATA[G H]]></given-names>
</name>
<name>
<surname><![CDATA[Andrews]]></surname>
<given-names><![CDATA[H F]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Relapse Risk after Discontinuation of Risperidone in Alzheimer&#8217;s Disease]]></article-title>
<source><![CDATA[N Engl J Med]]></source>
<year>2012</year>
<volume>367</volume>
<numero>16</numero>
<issue>16</issue>
<page-range>1497-507</page-range></nlm-citation>
</ref>
<ref id="B30">
<label>30</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Bravo-José]]></surname>
<given-names><![CDATA[P]]></given-names>
</name>
<name>
<surname><![CDATA[Einstein]]></surname>
<given-names><![CDATA[C A]]></given-names>
</name>
<name>
<surname><![CDATA[Sáez-Lleó]]></surname>
<given-names><![CDATA[C I]]></given-names>
</name>
<name>
<surname><![CDATA[Peris-Martí]]></surname>
<given-names><![CDATA[J F]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Deprescripción de antipsicóticos en pacientes institucionalizados con demencia]]></article-title>
<source><![CDATA[Farm Hosp]]></source>
<year>2019</year>
<volume>43</volume>
<numero>4</numero>
<issue>4</issue>
<page-range>140-5</page-range></nlm-citation>
</ref>
<ref id="B31">
<label>31</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Brodaty]]></surname>
<given-names><![CDATA[H]]></given-names>
</name>
<name>
<surname><![CDATA[Aerts]]></surname>
<given-names><![CDATA[L]]></given-names>
</name>
<name>
<surname><![CDATA[Harrison]]></surname>
<given-names><![CDATA[F]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Antipsychotic Deprescription for Older Adults in Long-term Care: The HALT Study]]></article-title>
<source><![CDATA[J Am Med Dir Assoc]]></source>
<year>2018</year>
<volume>19</volume>
<numero>7</numero>
<issue>7</issue>
<page-range>592-600.e7</page-range></nlm-citation>
</ref>
<ref id="B32">
<label>32</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Moth]]></surname>
<given-names><![CDATA[A E]]></given-names>
</name>
<name>
<surname><![CDATA[Hølmkjær]]></surname>
<given-names><![CDATA[P]]></given-names>
</name>
<name>
<surname><![CDATA[Holm]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Rozing]]></surname>
<given-names><![CDATA[M P]]></given-names>
</name>
<name>
<surname><![CDATA[Overbeck]]></surname>
<given-names><![CDATA[G]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[What Makes Deprescription of Psychotropic Drugs in Nursing Home Residents with Dementia so Challenging? A Qualitative Systematic Review of Barriers and Facilitators]]></article-title>
<source><![CDATA[Drugs Aging]]></source>
<year>2021</year>
<volume>38</volume>
<numero>8</numero>
<issue>8</issue>
<page-range>671-85</page-range></nlm-citation>
</ref>
<ref id="B33">
<label>33</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[van Leeuwen]]></surname>
<given-names><![CDATA[E]]></given-names>
</name>
<name>
<surname><![CDATA[Petrovic]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[van Driel]]></surname>
<given-names><![CDATA[M L]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Discontinuation of Long-Term Antipsychotic Drug Use for Behavioral and Psychological Symptoms in Older Adults &#8805;65 Years With Dementia]]></article-title>
<source><![CDATA[J Am Med Dir Assoc]]></source>
<year>2018</year>
<volume>19</volume>
<numero>11</numero>
<issue>11</issue>
<page-range>1009-14</page-range></nlm-citation>
</ref>
<ref id="B34">
<label>34</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Azermai]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Petrovic]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Engelborghs]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[The effects of abrupt antipsychotic discontinuation in cognitively impaired older persons: A pilot study]]></article-title>
<source><![CDATA[Aging Ment Health]]></source>
<year>2013</year>
<volume>17</volume>
<numero>1</numero>
<issue>1</issue>
<page-range>125-32</page-range></nlm-citation>
</ref>
<ref id="B35">
<label>35</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Rodolico]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Siafis]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[Bighelli]]></surname>
<given-names><![CDATA[I]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Antipsychotic dose reduction compared to dose continuation for people with schizophrenia]]></article-title>
<source><![CDATA[Cochrane Database Syst Rev]]></source>
<year>2022</year>
<numero>11</numero>
<issue>11</issue>
</nlm-citation>
</ref>
<ref id="B36">
<label>36</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Takeuchi]]></surname>
<given-names><![CDATA[H]]></given-names>
</name>
<name>
<surname><![CDATA[Remington]]></surname>
<given-names><![CDATA[G]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Immediate versus wait-and-gradual discontinuation in antipsychotic switching: A meta-analysis]]></article-title>
<source><![CDATA[J Psychopharmacol]]></source>
<year>2020</year>
<volume>34</volume>
<numero>8</numero>
<issue>8</issue>
<page-range>914-9</page-range></nlm-citation>
</ref>
<ref id="B37">
<label>37</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Sheehan]]></surname>
<given-names><![CDATA[R]]></given-names>
</name>
<name>
<surname><![CDATA[Hassiotis]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Reduction or discontinuation of antipsychotics for challenging behaviour in adults with intellectual disability: a systematic review]]></article-title>
<source><![CDATA[Lancet Psychiatry]]></source>
<year>2017</year>
<volume>4</volume>
<numero>3</numero>
<issue>3</issue>
<page-range>238-56</page-range></nlm-citation>
</ref>
<ref id="B38">
<label>38</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Gao]]></surname>
<given-names><![CDATA[R L]]></given-names>
</name>
<name>
<surname><![CDATA[Lim]]></surname>
<given-names><![CDATA[K S]]></given-names>
</name>
<name>
<surname><![CDATA[Luthra]]></surname>
<given-names><![CDATA[A S]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Discontinuation of antipsychotics treatment for elderly patients within a specialized behavioural unit: a retrospective review]]></article-title>
<source><![CDATA[Int J Clin Pharm]]></source>
<year>2021</year>
<volume>43</volume>
<numero>1</numero>
<issue>1</issue>
<page-range>212-9</page-range></nlm-citation>
</ref>
<ref id="B39">
<label>39</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Begemann]]></surname>
<given-names><![CDATA[M J H]]></given-names>
</name>
<name>
<surname><![CDATA[Thompson]]></surname>
<given-names><![CDATA[I A]]></given-names>
</name>
<name>
<surname><![CDATA[Veling]]></surname>
<given-names><![CDATA[W]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Antipsychotic maintenance versus dose-reduction/discontinuation in first episode psychosis: the HAMLETT trial]]></article-title>
<source><![CDATA[Trials]]></source>
<year>2020</year>
<volume>21</volume>
<numero>1</numero>
<issue>1</issue>
</nlm-citation>
</ref>
<ref id="B40">
<label>40</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Calsolaro]]></surname>
<given-names><![CDATA[V]]></given-names>
</name>
<name>
<surname><![CDATA[Femminella]]></surname>
<given-names><![CDATA[G D]]></given-names>
</name>
<name>
<surname><![CDATA[Rogani]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Behavioral and Psychological Symptoms in Dementia (BPSD) and the Use of Antipsychotics]]></article-title>
<source><![CDATA[Pharmaceuticals (Basel)]]></source>
<year>2021</year>
<volume>14</volume>
<numero>3</numero>
<issue>3</issue>
</nlm-citation>
</ref>
<ref id="B41">
<label>41</label><nlm-citation citation-type="book">
<collab>National Institute for Health and Care Excellence (NICE)</collab>
<source><![CDATA[Dementia: Assessment, management and support for people living with dementia and their carers]]></source>
<year>2018</year>
<publisher-name><![CDATA[NICE]]></publisher-name>
</nlm-citation>
</ref>
<ref id="B42">
<label>42</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Huang]]></surname>
<given-names><![CDATA[Y Y]]></given-names>
</name>
<name>
<surname><![CDATA[Teng]]></surname>
<given-names><![CDATA[T]]></given-names>
</name>
<name>
<surname><![CDATA[Shen]]></surname>
<given-names><![CDATA[X N]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Pharmacological treatments for psychotic symptoms in dementia: A systematic review with pairwise and network meta-analysis]]></article-title>
<source><![CDATA[Ageing Res Rev]]></source>
<year>2022</year>
<volume>75</volume>
</nlm-citation>
</ref>
<ref id="B43">
<label>43</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Ballard]]></surname>
<given-names><![CDATA[C]]></given-names>
</name>
<name>
<surname><![CDATA[Powell]]></surname>
<given-names><![CDATA[I]]></given-names>
</name>
<name>
<surname><![CDATA[James]]></surname>
<given-names><![CDATA[I]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Can psychiatric liaison reduce neuroleptic use and reduce health service utilization for dementia patients in care facilities]]></article-title>
<source><![CDATA[Int J Geriatr Psychiatry]]></source>
<year>2022</year>
<volume>17</volume>
<page-range>140-5</page-range></nlm-citation>
</ref>
<ref id="B44">
<label>44</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Sanfélix-Gimeno]]></surname>
<given-names><![CDATA[G]]></given-names>
</name>
<name>
<surname><![CDATA[Cervera-Casino]]></surname>
<given-names><![CDATA[P]]></given-names>
</name>
<name>
<surname><![CDATA[Peiró]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Effectiveness of safety warnings in atypical antipsychotic drugs: an interrupted time-series analysis in Spain]]></article-title>
<source><![CDATA[Drug Saf]]></source>
<year>2009</year>
<volume>32</volume>
<numero>11</numero>
<issue>11</issue>
<page-range>1075-87</page-range></nlm-citation>
</ref>
<ref id="B45">
<label>45</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Kales]]></surname>
<given-names><![CDATA[H C]]></given-names>
</name>
<name>
<surname><![CDATA[Maust]]></surname>
<given-names><![CDATA[D T]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Good Intentions, But What About Unintended Consequences?]]></article-title>
<source><![CDATA[Drug Saf]]></source>
<year>2017</year>
<volume>40</volume>
<numero>8</numero>
<issue>8</issue>
<page-range>647-9</page-range></nlm-citation>
</ref>
<ref id="B46">
<label>46</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Colla]]></surname>
<given-names><![CDATA[C H]]></given-names>
</name>
<name>
<surname><![CDATA[Mainor]]></surname>
<given-names><![CDATA[A J]]></given-names>
</name>
<name>
<surname><![CDATA[Hargreaves]]></surname>
<given-names><![CDATA[C]]></given-names>
</name>
<name>
<surname><![CDATA[Sequist]]></surname>
<given-names><![CDATA[T]]></given-names>
</name>
<name>
<surname><![CDATA[Morden]]></surname>
<given-names><![CDATA[N]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Interventions Aimed at Reducing Use of Low-Value Health Services: A Systematic Review]]></article-title>
<source><![CDATA[Med Care Res Rev]]></source>
<year>2017</year>
<volume>74</volume>
<numero>5</numero>
<issue>5</issue>
<page-range>507-50</page-range></nlm-citation>
</ref>
<ref id="B47">
<label>47</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Colquhoun]]></surname>
<given-names><![CDATA[H L]]></given-names>
</name>
<name>
<surname><![CDATA[Squires]]></surname>
<given-names><![CDATA[J E]]></given-names>
</name>
<name>
<surname><![CDATA[Kolehmainen]]></surname>
<given-names><![CDATA[N]]></given-names>
</name>
<name>
<surname><![CDATA[Fraser]]></surname>
<given-names><![CDATA[C]]></given-names>
</name>
<name>
<surname><![CDATA[Grimshaw]]></surname>
<given-names><![CDATA[J M]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Methods for designing interventions to change healthcare professionals&#8217; behavior: a systematic review]]></article-title>
<source><![CDATA[Implement Sci]]></source>
<year>2017</year>
<volume>12</volume>
<numero>1</numero>
<issue>1</issue>
</nlm-citation>
</ref>
<ref id="B48">
<label>48</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Cohen-Mansfield]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[The Rights of Persons with Dementia and Their Meanings]]></article-title>
<source><![CDATA[J Am Med Dir Assoc]]></source>
<year>2021</year>
<volume>22</volume>
<numero>7</numero>
<issue>7</issue>
<page-range>1381-5</page-range></nlm-citation>
</ref>
</ref-list>
</back>
</article>
